Home medical equipment company AdaptHealth Corp (NASDAQ:AHCO) revealed on Friday that it has entered into a definitive agreement to acquire the Patient Care Solutions (PCS) business from McKesson Corporation.
Subject to customary closing conditions, the acquisition is expected to close in December 2019.
AdaptHealth stated that the total investment, including restructuring costs until the business is fully integrated on AdaptHealth's platform in the latter half of 2020, is anticipated to be approximately USD30m.
PCS provides wound care supplies, ostomy supplies, urological supplies, incontinence supplies, diabetic care supplies and breast pumps directly to patients across the US. The company said it maintains extensive national relationships with physicians, medical facilities and customers, currently serving all 50 states. For the trailing 12 months ended 31 October 2019, it generated net revenues of about USD134m.
Under the terms of the agreement, AdaptHealth will sign a supply and distribution agreement with McKesson Corporation with respect to PCS's HME service lines.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies